BriefCase vs TREWS (Targeted Real-Time Early Warning System)

BriefCase offers both cloud and mobile app deployments, indicating flexibility for users to access the solution from various devices and locations. Its integration with PACS, RIS, and EHR systems, along with customizable communication protocols and automated follow-up tracking, suggests a streamlined workflow designed for ease of use within existing clinical environments. TREWS also integrates with EHRs and aims to provide actionable insights within existing workflows, but BriefCase's explicit mention of mobile access for care team collaboration and comprehensive audit trails points to a more robust and accessible user experience for communication and collaboration.

TREWS has demonstrated a significant clinical impact by reducing mortality from sepsis by 18% and leading to sepsis treatments occurring 1.85 hours earlier. This is a direct, patient-outcome-focused benefit. While BriefCase has shown to reduce overlooked cases of incidental pulmonary embolisms and improve diagnostic accuracy, it does not explicitly state a direct reduction in patient mortality.

Both tools utilize an enterprise pricing model with custom pricing based on hospital size and integration requirements, making a direct comparison of value difficult without specific quotes. BriefCase's pricing starts at approximately $50,000 per site per year, with additional modules costing $8,000 to $15,000, which may be a barrier for smaller hospitals. Neither company offers transparent public pricing tiers, making it challenging to definitively declare a winner in terms of overall value without more detailed financial information.

BriefCase, as part of the Aidoc platform, boasts over 500 hospital customers globally and has numerous FDA clearances across various pathologies, including 14 indications in a single workflow. This extensive customer base and broad regulatory clearance demonstrate a high level of enterprise readiness and proven scalability. While TREWS has secured FDA clearance for its sepsis monitor and integrates with major EHRs like Epic and Cerner, its customer count is not specified, and its focus appears more specialized in critical care.

TREWS features an adaptive AI that learns from clinician feedback and analyzes multi-modal patient data (vitals, labs, notes), which is a significant innovative aspect for continuous improvement and personalized insights. It is also the first FDA-cleared continuous AI sepsis monitor. BriefCase leverages AI for critical finding detection and communication, and Aidoc has developed a 'Clinical AI Reasoning Engine (CARE) Foundation Model', but TREWS's adaptive learning and multi-modal data analysis for early warning systems represent a distinct innovative edge in real-time clinical intelligence.

Both companies are enterprise-focused, implying dedicated support and documentation. BriefCase mentions comprehensive audit trails, which can be a form of documentation for system usage. Bayesian Health's developer surface includes an engineering blog and support, indicating resources for technical users. However, without specific details on the breadth and accessibility of their support channels, training programs, or documentation libraries, it is difficult to distinguish a clear winner.